Updated on 2026/08/16

写真a

 
HONDA Hiroyuki
 
Organization
School of Medicine Department of Respiratory Medicine and Allergology Assistant Professor
Title
Assistant Professor
External link

Degree

  • MD, PhD ( 2019.3   Sapporo Medical University )

Papers

  • Real-world clinical data on adult respiratory syncytial virus infection in a Japanese community hospital: Emphasis on positivity rate, older adults, and pneumonia cases. International journal

    Hiroyuki Honda, Koji Kuronuma, Yutaro Nagano, Kanami Nagano, Kojirou Uemura, Midori Hashimoto, Kaoru Nishiyama, Hirofumi Chiba

    Respiratory investigation   64 ( 2 )   101371 - 101371   2026.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Information on the incidence and clinical characteristics of respiratory syncytial virus (RSV) infections among adults remains limited in Japan. In this study, we aimed to clarify these aspects among adult outpatients at our institution. METHODS: This single-center, retrospective observational study included outpatients aged 18 years and older who presented with fever or respiratory symptoms and underwent multiplex PCR testing of nasopharyngeal specimens between April 2021 and March 2025. We assessed the RSV positive rate, underlying comorbidities, and hospitalization rate. For those with pneumonia, we analyzed their imaging findings and sputum culture results. Clinical characteristics were also compared between hospitalized and nonhospitalized patients aged 60 years or older. RESULTS: The overall positive rate of RSV infection over the 4 years was 2.3 %. Among individuals aged 60 years and older, the positive rate was 2.3 %. Of the 31 hospitalized cases, 29 were aged 60 years or older, accounting for 36.3 % of all RSV-positive patients in this age group. Age significantly differed between the hospitalized and nonhospitalized groups aged 60 and older. Among 24 patients with pneumonia who underwent computed tomography scans, 11 had positive sputum cultures. Consolidation was significantly more frequent in the 11 culture-positive cases than in the remaining 13 cases. CONCLUSIONS: RSV infection accounted for 2.3 % of adult outpatient cases, with a notably high hospitalization rate in older adults. These findings highlight RSV as an important respiratory pathogen in older adults, underscoring the need to expand diagnostic testing and preventive strategies in this population.

    DOI： 10.1016/j.resinv.2026.101371

    PubMed

    researchmap

  • Influence of renal function and daptomycin dose on clinical effectiveness and adverse events in Japanese pediatric patients: A multicenter retrospective observational study. International journal

    Chihiro Shiraishi, Hideo Kato, Jun Hirai, Naoya Nishiyama, Takayuki Inagaki, Nobuyuki Ashizawa, Masashi Nakamatsu, Kazuko Yamamoto, Yasuhiro Miyagawa, Hiroyuki Honda, Satoshi Kakiuchi, Ayumi Fujita, Masato Tashiro, Takeshi Tanaka, Koichi Izumikawa, Mao Hagihara, Nobuhiro Asai, Nobuaki Mori, Hiroshige Mikamo, Takuya Iwamoto

    PloS one   20 ( 7 )   e0327993   2025

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Data on the clinical effectiveness and adverse events of daptomycin in pediatric patients, considering dosage and renal function, are limited. AIM: In this study, we aimed to investigate the clinical effectiveness of daptomycin, incidence of related adverse events, and associations between clinical outcomes and risk factors, including dosage and renal function, in pediatric patients. METHODS: Medical records of pediatric patients treated with daptomycin between September 2011 and December 2022, were retrospectively reviewed. Clinical effectiveness was categorized as cure, improvement, failure, or non-evaluable. The clinical success rate was defined as the sum of cured and improved cases. We classified doses based on the approved ranges: underdose (>1 mg/kg less than the approved dose), adequate dose (approved dose ±1 mg/kg), and overdose (>1 mg/kg more than the approved dose). Obesity was defined as a body mass index ≥ 30 kg/m2, with adjusted body weight used for dosing in these patients. FINDINGS: We enrolled 54 patients, achieving a clinical success rate of 91%. Four (7%) patients died, particularly those with microbiological failure (P = 0.004) and underdosing (P < 0.001). The underdose group comprised a higher proportion of younger patients (P = 0.020). Additionally, seven (13%) patients experienced daptomycin-related adverse events, including creatine phosphokinase elevation, eosinophilic pneumonia, rhabdomyolysis, liver failure, and drug fever, occurring regardless of renal function. Five patients received an approved dose, while two received an overdose. CONCLUSION: Adequate daptomycin dosing improved clinical effectiveness and the mortality rate. However, continuous monitoring of adverse events remains critical for patients receiving the approved dose, including those with a normal renal function.

    DOI： 10.1371/journal.pone.0327993

    PubMed

    researchmap

  • 左側全無気肺による急性呼吸不全を呈したアレルギー性気管支肺アスペルギルス症の1例

    本田 宏幸, 佐藤 亮, 北村 智香子, 篠崎 鮎香, 須藤 悠太

    日本呼吸器学会誌   11 ( 5 )   280 - 285   2022.9

    　More details

  • 肺腺癌十二指腸転移による消化管出血に対しPembrolizumabを併用した化学療法が奏功し止血が得られた1例

    佐藤 亮, 臺 鮎香, 本田 宏幸, 須藤 悠太

    肺癌   61 ( 6 )   709 - 709   2021.10

    　More details

    Language：Japanese   Publisher：(NPO)日本肺癌学会  

    Ichushi

    researchmap

  • In Vitro Derivation of Fluoroquinolone-Resistant Mutants from Multiple Lineages of Haemophilus influenzae and Identification of Mutations Associated with Fluoroquinolone Resistance. International journal

    Hiroyuki Honda, Toyotaka Sato, Masaaki Shinagawa, Yukari Fukushima, Chie Nakajima, Yasuhiko Suzuki, Koji Kuronuma, Satoshi Takahashi, Hiroki Takahashi, Shin-Ichi Yokota

    Antimicrobial agents and chemotherapy   64 ( 2 )   2020.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Haemophilus influenzae is a pathogenic bacterium that causes respiratory and otolaryngological infections. The increasing prevalence of β-lactamase-negative high-level ampicillin-resistant H. influenzae (high-BLNAR) is a clinical concern. Fluoroquinolones are alternative agents to β-lactams. However, the emergence and increasing prevalence of fluoroquinolone-resistant H. influenzae have been reported. The current risk of fluoroquinolone resistance in H. influenzae (especially in high-BLNAR) has not yet been evaluated. Here, we examined the development of fluoroquinolone resistance in fluoroquinolone-susceptible clinical H. influenzae isolates in vitro during passaging in the presence of moxifloxacin (from 0.03 to 128 mg/liter). Twenty-nine isolates were examined. Seventeen isolates (58.6%) showed reduced moxifloxacin susceptibility, and 10 of these 17 isolates (34.5% of all isolates) exceeded the Clinical and Laboratory Standards Institute breakpoint for moxifloxacin (MIC of >1 mg/liter) after repeat cultivation on moxifloxacin-containing agar. Seven of these ten isolates were high-BLNAR and represented multiple lineages. We identified 56 novel mutations in 45 genes induced during the development of fluoroquinolone resistance, except the defined quinolone resistance-determining regions (Ser84Leu and Asp88Tyr/Gly/Asn in GyrA and Gly82Asp, Ser84Arg, and Glu88Lys in ParC). Glu153Leu and ΔGlu606 in GyrA, Ser467Tyr and Glu469Asp in GyrB, and ompP2 mutations were novel mutations contributing to fluoroquinolone resistance in H. influenzae In conclusion, H. influenzae clinical isolates from multiple lineages can acquire fluoroquinolone resistance by multiple novel mutations. The higher rate of derivation of fluoroquinolone-resistant H. influenzae from high-BLNAR than β-lactamase-negative ampicillin-susceptible isolates (P = 0.01) raises the possibility of the emergence and spread of fluoroquinolone-resistant high-BLNAR in the clinical setting.

    DOI： 10.1128/AAC.01500-19

    PubMed

    researchmap

  • Contribution of Novel Amino Acid Alterations in PmrA or PmrB to Colistin Resistance in mcr-Negative Escherichia coli Clinical Isolates, Including Major Multidrug-Resistant Lineages O25b:H4-ST131-H30Rx and Non-x. International journal

    Toyotaka Sato, Tsukasa Shiraishi, Yoshiki Hiyama, Hiroyuki Honda, Masaaki Shinagawa, Masaru Usui, Koji Kuronuma, Naoya Masumori, Satoshi Takahashi, Yutaka Tamura, Shin-Ichi Yokota

    Antimicrobial agents and chemotherapy   62 ( 9 )   2018.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Colistin is a last-line drug for multidrug-resistant Gram-negative bacteria. We previously reported four plasmid-mediated colistin resistance (mcr) gene-negative colistin-resistant Escherichia coli clinical isolates, including the major pathogenic and fluoroquinolone-resistant strains O25b:H4-ST131-H30Rx (isolates SRE34 and SRE44; MIC for colistin = 16 mg/liter), non-x (SME296; MIC = 8 mg/liter), and O18-ST416 (SME222; MIC = 4 mg/liter). In this study, we investigated the colistin resistance mechanism and identified novel amino acid substitutions or deletions in the PmrAB two-component system that activates eptA (encoding a phosphoethanolamine transferase) and arnT (encoding an undecaprenyl phosphate-alpha-4-amino-4-deoxy-l-arabinose arabinosyl transferase) in all colistin-resistant isolates. SRE34 possessed deletion Δ27-45 (LISVFWLWHESTEQIQLFE) in PmrB, SRE44 possessed substitution L105P in PmrA, and both SME222 and SME296 included substitution G206D in PmrB. Matrix-assisted laser desorption ionization-time of flight mass spectrometry revealed that lipid A is modified with phosphoethanolamine in all four isolates. Deletion of pmrAB decreased colistin MICs to 0.5 mg/liter and lowered eptA and arnT expression. Chromosomal replacement of mutated pmrA or pmrB in colistin-susceptible O25b:H4-ST131 strain SME98 (colistin MIC = 0.5 mg/liter) increased the colistin MIC to that of the respective parent colistin-resistant isolate. In addition, SME98 mutants in which pmrAB was replaced with mutated pmrAB showed no significant differences in bacterial growth and competition culture from the parent strain, except for the mutant with L105P in PmrA, whose growth was significantly suppressed in the presence of the parent strain. In conclusion, some O25b:H4-ST131 strains appear to acquire colistin resistance via phosphoethanolamine modification of lipid A through amino acid changes in PmrAB, and the amino acid changes in PmrB do not influence bacterial growth.

    DOI： 10.1128/AAC.00864-18

    PubMed

    researchmap

  • Multiclonal Expansion and High Prevalence of β-Lactamase-Negative Haemophilus influenzae with High-Level Ampicillin Resistance in Japan and Susceptibility to Quinolones. International journal

    Hiroyuki Honda, Toyotaka Sato, Masaaki Shinagawa, Yukari Fukushima, Chie Nakajima, Yasuhiko Suzuki, Tsukasa Shiraishi, Koji Kuronuma, Satoshi Takahashi, Hiroki Takahashi, Shin-Ichi Yokota

    Antimicrobial agents and chemotherapy   62 ( 9 )   2018.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    β-Lactam-resistant Haemophilus influenzae is a clinical concern. A high prevalence (>40%) of β-lactamase-negative high-level ampicillin-resistant H. influenzae (high-BLNAR) isolates in Japan has been reported. However, the reasons for the expansion are unknown. High-BLNAR strains possess an amino acid substitution, either Asn526Lys (group III) or Arg517His (group III-like) in addition to Ser385Thr, in penicillin-binding protein 3 (PBP3). To determine the current prevalence of high-BLNAR strains and the mechanisms behind their expansion in Japan, their prevalence, PBP3 types, multilocus sequence types, and susceptibilities to quinolones approved in Japan as alternatives were determined. Sixty percent of H. influenzae clinical isolates (62/104 isolates) were β-lactamase-negative ampicillin-resistant H. influenzae (BLNAR) strains. Among BLNAR isolates, 92% (57/62 isolates) were high-BLNAR strains. Most isolates were classified as belonging to group III, which contained many genotypes (11 PBP3 types and 25 sequence types). These results indicated that the expansion of high-BLNAR isolates was multiclonal and such strains are still predominant in Japanese clinical settings. One high-BLNAR isolate harbored the novel amino acid substitution Asn526Met in addition to Ser385Thr in PBP3, suggesting a new group (group IV). No quinolone-resistant H. influenzae isolates were identified. The MICs for the quinolones (moxifloxacin, garenoxacin, and tosufloxacin) were similar to that for levofloxacin, whereas sitafloxacin exhibited a lower MIC. However, we obtained 4 H. influenzae isolates with decreased quinolone susceptibility with the amino acid substitution Ser84Leu in GyrA, and 3 of those isolates were high-BLNAR isolates. In summary, this study shows that multiclonal high-BLNAR strains predominate in a Japanese university hospital. Isolates remain sensitive to quinolones, but vigilance is required to prevent the development of fluoroquinolone resistance in high-BLNAR strains.

    DOI： 10.1128/AAC.00851-18

    PubMed

    researchmap

  • Response to pneumococcal vaccine in interstitial lung disease patients: Influence of systemic immunosuppressive treatment. International journal

    Koji Kuronuma, Hiroyuki Honda, Tessei Mikami, Atsushi Saito, Kimiyuki Ikeda, Mitsuo Otsuka, Hirofumi Chiba, Gen Yamada, Toyotaka Sato, Shin-Ichi Yokota, Hiroki Takahashi

    Vaccine   36 ( 33 )   4968 - 4972   2018.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Interstitial lung diseases (ILD) are severe respiratory diseases, and ILD patients are treated with corticosteroid and immunosuppressive agents. However, it is unclear whether these medications influence the response of pneumococcal vaccine. OBJECTIVES: We examined the immunogenicity of pneumococcal vaccines (PPSV23 and PCV13) in ILD patients undergoing immunosuppressive treatment. METHODS: ILD patients who were regularly followed at the outpatient clinic were enrolled. Sera were collected before and 4-8 weeks after vaccination. Serotype-specific immunoglobulin G (IgG) concentrations against pneumococcal serotype 19F were measured by ELISA. RESULTS: IgG concentrations to serotype 19F were increased in all groups in response to the vaccine. Both PCV13 and PPSV23 induced IgG concentrations in patients immunized for the first time. Response rates for the ILD group were comparable with those for the ILD group undergoing corticosteroid therapy. Only idiopathic pulmonary fibrosis patients undergoing immunosuppressive therapy had a significantly lower response.

    DOI： 10.1016/j.vaccine.2018.06.062

    PubMed

    researchmap

  • Whole genome analysis of a multidrug-resistant Streptococcus pneumoniae isolate from a patient with invasive pneumococcal infection developing disseminated intravascular coagulation. International journal

    Yasuo Ohkoshi, Toyotaka Sato, Takayuki Wada, Yukari Fukushima, Hiromi Murabayashi, Yasunari Takakuwa, Kaoru Nishiyama, Hiroyuki Honda, Tsukasa Shiraishi, Koji Kuronuma, Hiroki Takahashi, Chie Nakajima, Yasuhiko Suzuki, Shin-Ichi Yokota

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy   24 ( 8 )   674 - 681   2018.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Multidrug-resistant Streptococcus pneumoniae strains were isolated from blood and sputum of a patient with disseminated intravascular coagulation in Sapporo city, Japan. These antibiograms were only susceptible to vancomycin, linezolid, daptomycin, some carbapenems, and some fluoroquinolones. Identical antibiograms, serotypes (19F), and sequence types (ST10017) suggested a shared origin of these isolates. Only one ST10017 strain has been isolated in the same city in Japan previously (2014), and the 2014 isolate is still susceptible to macrolides. The whole genome of the blood-derived isolate was sequenced. The strain harbored resistance mutations in parC, gyrA, pbp1a, pbp2a, pbp2b, and pbp2x, and harbored the resistance genes, ermB and tetM. The nucleotide sequences of parC and pbp2x genes of strain MDRSPN001 were clearly different from those of other S. pneumoniae strains and were similar to those of oral streptococci strains. These findings suggest that strain MDRSPN001 has been rapidly and drastically evolving multidrug resistance by gene replacement and accumulation of genes originating from other strains, such as oral streptococci, Streptococcus mitis.

    DOI： 10.1016/j.jiac.2018.01.012

    PubMed

    researchmap

  • 経気管支生検を施行した線維形成型悪性胸膜中皮腫の1剖検例

    本田 宏幸, 森 裕二, 石川 立, 小野 貴広, 中田 尚志, 高橋 弘毅

    肺癌   58 ( 1 )   29 - 34   2018.2

    　More details

  • 大腸菌臨床分離株におけるepidemic clone ST131のコリスチンおよびチゲサイクリン耐性(Colistin and tigecycline resistance in an epidemic clone, ST131, Escherichia coli clinical isolates)

    佐藤 豊孝, 臼井 優, 品川 雅明, 福田 昭, 本田 宏幸, 白石 宗, 田村 豊, 高橋 聡, 横田 伸一

    日本細菌学雑誌   73 ( 1 )   146 - 146   2018.2

    　More details

    Language：English   Publisher：日本細菌学会  

    Ichushi

    researchmap

  • Tigecycline Nonsusceptibility Occurs Exclusively in Fluoroquinolone-Resistant Escherichia coli Clinical Isolates, Including the Major Multidrug-Resistant Lineages O25b:H4-ST131-H30R and O1-ST648. Reviewed

    Toyotaka Sato, Yuuki Suzuki, Tsukasa Shiraishi, Hiroyuki Honda, Masaaki Shinagawa, Soh Yamamoto, Noriko Ogasawara, Hiroki Takahashi, Satoshi Takahashi, Yutaka Tamura, Shin-ichi Yokota

    Antimicrob Agents Chemother.   61 ( 2 )   2017.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1128/AAC.01654-16

    Web of Science

    researchmap

  • Pathogenic Lineage of mcr-Negative Colistin-Resistant Escherichia coli, Japan, 2008-2015 Reviewed

    Toyotaka Sato, Akira Fukuda, Yuuki Suzuki, Tsukasa Shiraishi, Hiroyuki Honda, Masaaki Shinagawa, Soh Yamamoto, Noriko Ogasawara, Masaru Usui, Hiroki Takahashi, Satoshi Takahashi, Yutaka Tamura, Shin-ichi Yokota

    EMERGING INFECTIOUS DISEASES   22 ( 12 )   2223 - 2225   2016.12

    　More details

  • 腫瘍随伴症候群が疑われる多発性筋炎を発症した肺扁平上皮癌の1例

    石川 立, 本田 宏幸, 小野 貴広, 中田 尚志, 北村 公一, 森 裕二

    肺癌   56 ( 4 )   278 - 283   2016.8

    　More details

  • 喘息コントロールに対するSMART療法の検討

    田中 悠祐, 小寺 祐貴, 本田 宏幸, 山添 雅己, 高橋 隆二

    アレルギー   64 ( 3-4 )   557 - 557   2015.4

    　More details

    Language：Japanese   Publisher：(一社)日本アレルギー学会  

    Ichushi

    researchmap

▼display all

MISC

▼display all